Institution
Beaumont Health
Nonprofit•Royal Oak, Michigan, United States•
About: Beaumont Health is a nonprofit organization based out in Royal Oak, Michigan, United States. It is known for research contribution in the topics: Medicine & Population. The organization has 1483 authors who have published 1448 publications receiving 15407 citations. The organization is also known as: William Beaumont Health System & Beaumont Hospitals.
Topics: Medicine, Population, Cancer, Breast cancer, Arthroplasty
Papers published on a yearly basis
Papers
More filters
••
TL;DR: Patients with early- and late-onset PICC bloodstream infections at this institution are compared and significant differences in microbiologic etiologies are found.
Abstract: The risks and microbiology for peripherally inserted central catheters (PICCs) are less well described than those for traditional central catheters, particularly as they pertain to duration of catheterization. We compared patients with early- and late-onset PICC bloodstream infections at our institution and found significant differences in microbiologic etiologies.
11 citations
••
Henry Ford Hospital1, Johns Hopkins University2, Allegheny Health Network3, University of Rochester Medical Center4, Mount Sinai Hospital5, Thomas Jefferson University Hospital6, NewYork–Presbyterian Hospital7, University of Toronto8, Università Campus Bio-Medico9, University of Erlangen-Nuremberg10, Kaiser Permanente11, University of Mississippi Medical Center12, Radboud University Nijmegen13, Stanford University14, University of Arkansas for Medical Sciences15, Virginia Mason Medical Center16, Beaumont Health17, Oakland University18, Cedars-Sinai Medical Center19, Sutter Health20, The Ohio State University Wexner Medical Center21
TL;DR: In this article, the authors report outcomes with the full-thickness resection device (FTRD) for the resection of appendiceal lesions and identify factors associated with the occurrence of appendicitis.
Abstract: Background Endoscopic resection of lesions involving the appendiceal orifice remains a challenge. We aimed to report outcomes with the full-thickness resection device (FTRD) for the resection of appendiceal lesions and identify factors associated with the occurrence of appendicitis. Methods This was a retrospective study at 18 tertiary-care centers (USA 12, Canada 1, Europe 5) between November 2016 and August 2020. Consecutive patients who underwent resection of an appendiceal orifice lesion using the FTRD were included. The primary outcome was the rate of R0 resection in neoplastic lesions, defined as negative lateral and deep margins on post-resection histologic evaluation. Secondary outcomes included the rates of: technical success (en bloc resection), clinical success (technical success without need for further surgical intervention), post-resection appendicitis, and polyp recurrence. Results 66 patients (32 women; mean age 64) underwent resection of colonic lesions involving the appendiceal orifice (mean [standard deviation] size, 14.5 (6.2) mm), with 40 (61 %) being deep, extending into the appendiceal lumen. Technical success was achieved in 59/66 patients (89 %), of which, 56 were found to be neoplastic lesions on post-resection pathology. Clinical success was achieved in 53/66 (80 %). R0 resection was achieved in 52/56 (93 %). Of the 58 patients in whom EFTR was completed who had no prior history of appendectomy, appendicitis was reported in 10 (17 %), with six (60 %) requiring surgical appendectomy. Follow-up colonoscopy was completed in 41 patients, with evidence of recurrence in five (12 %). Conclusions The FTRD is a promising non-surgical alternative for resecting appendiceal lesions, but appendicitis occurs in 1/6 cases.
11 citations
••
TL;DR: This case demonstrates the necessity of keeping flecainide toxicity on the physician's differential for patients who are taking the drug, as well as what electrocardiogram findings suggest it as the etiology.
Abstract: Background Flecainide is a class Ic antidysrhythmic agent used to prevent and treat both ventricular and supraventricular tachycardias, including atrial fibrillation, atrioventricular nodal re-entrant tachycardia, and Wolff-Parkinson-White syndrome. Flecainide can cause serious side effects, including cardiac arrest, dysrhythmias, and heart failure. Despite its growing use, the presenting signs and symptoms of flecainide toxicity are not familiar to most clinicians. In particular, our patient's particular presentation of acute kidney injury (AKI) resulting in flecainide accumulation is high risk for missed diagnosis in the emergency department. Case Report A 58-year-old woman presented with altered mental status and hypoxia that was later found to be secondary to sepsis. Medical history was notable for atrial fibrillation, for which she was on flecainide. Laboratory results were notable for hypokalemia and an AKI. Her wide complex tachycardia on admission was ultimately attributed to flecainide toxicity in the setting of AKI. Six days after presentation, it was found that her flecainide level was in the toxic range at 2.02 μg/mL (normal range 0.20–1.00 μg/mL, toxic >1.50 μg/mL). Why Should an Emergency Physician Be Aware of This? Flecainide intoxication is rare but serious due to the potential for cardiogenic shock. Its diagnosis can be difficult, as the flecainide serum level may take days to result. This case demonstrates the necessity of keeping flecainide toxicity on the physician's differential for patients who are taking the drug, as well as what electrocardiogram findings suggest it as the etiology. Treatment can be lifesaving if initiated promptly.
11 citations
••
TL;DR: In this paper, the authors proposed a method to improve the local disease control and relieve symptoms of metastasis in the spinal vertebrae, which can cause pain, neurological disability, and reduce quality of life.
Abstract: Many cancers result in metastasis in the spinal vertebrae, which can cause pain, neurological disability, and reduce quality of life [1,2]. To improve the local disease control and relieve symptoms...
11 citations
••
TL;DR: A significant benefit to OS is supported by incorporating radiotherapy as a component of trimodality therapy for patients with localized MPM compared to only surgery and chemotherapy, and radiotherapy does not provide a significant overall survival benefit for Patients with regional or metastatic disease.
11 citations
Authors
Showing all 1494 results
Name | H-index | Papers | Citations |
---|---|---|---|
Barry P. Rosen | 102 | 529 | 36258 |
Praveen Kumar | 88 | 1339 | 35718 |
George S. Wilson | 88 | 716 | 33034 |
Ahmed Ali | 61 | 728 | 15197 |
Di Yan | 61 | 295 | 11437 |
David P. Wood | 59 | 243 | 12154 |
Brian D. Kavanagh | 58 | 322 | 15865 |
James A. Goldstein | 49 | 193 | 12312 |
Kenneth M. Peters | 46 | 197 | 6513 |
James M. Robbins | 45 | 157 | 8489 |
Bin Nan | 44 | 139 | 5321 |
Inga S. Grills | 43 | 217 | 6343 |
Sachin Kheterpal | 43 | 169 | 8545 |
Craig W. Stevens | 42 | 164 | 6598 |
Thomas Guerrero | 41 | 93 | 5018 |